BiotechTube

ALGLUCOSIDASE ALFA (MYOZYME)

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Glycogen Storage Disease Type II

Conditions

Glycogen Storage Disease Type II

Trial Timeline

Dec 4, 2018 → Dec 30, 2020

NCT ID
NCT03687333

About ALGLUCOSIDASE ALFA (MYOZYME)

ALGLUCOSIDASE ALFA (MYOZYME) is a approved stage product being developed by Sanofi for Glycogen Storage Disease Type II. The current trial status is completed. This product is registered under clinical trial identifier NCT03687333. Target conditions include Glycogen Storage Disease Type II.

What happened to similar drugs?

2 of 6 similar drugs in Glycogen Storage Disease Type II were approved

Approved (2) Terminated (0) Active (4)
✅Avalglucosidase alfa (GZ402666)SanofiApproved
✅Avalglucosidase alfaSanofiApproved
🔄avalglucosidase alfaSanofiPhase 3
🔄Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)SanofiPhase 3
🔄Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3
🔄Oral prednisolone + Placebo for oral prednisoloneUltragenyx PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03687333ApprovedCompleted

Competing Products

20 competing products in Glycogen Storage Disease Type II

See all competitors
ProductCompanyStageHype Score
mRNA-3745ModernaPhase 2
0
alglucosidase alfaSanofiPre-clinical
26
avalglucosidase alfaSanofiPhase 3
44
MyozymeSanofiPhase 2/3
38
MyozymeSanofiPre-clinical
26
Avalglucosidase AlfaSanofiPhase 2
35
MyozymeSanofiPhase 2/3
38
Avalglucosidase alfa (GZ402666)SanofiApproved
47
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)SanofiPhase 3
40
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)SanofiPhase 2
39
Alglucosidase alfaSanofiPhase 2
35
Avalglucosidase alfaSanofiApproved
50
MyozymeSanofiPhase 1/2
32
Alglucosidase alfa GZ419829SanofiPre-clinical
30
alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])SanofiPre-clinical
26
alglucosidase alfaSanofiPre-clinical
26
Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3
44
BEAM-301: Single dose of BEAM-301 administered by IVBeam TherapeuticsPhase 1/2
33
Oral prednisolone + Placebo for oral prednisoloneUltragenyx PharmaceuticalPhase 3
34
UX053 + Antipyretic + H2 Blocker + H1 BlockerUltragenyx PharmaceuticalPhase 1/2
18